Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has awarded two research grants worth $4m to National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) to support the development of advanced melanoma treatment.
Subscribe to our email newsletter
The grant is intended to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor.
GSK2118436 is an investigational drug that is orally bioavailable and inhibits BRAF, while GSK1120212 which is also an investigational drug is orally bioavailable and inhibits MEK.
According to the company, BRAF mutations have proven to be strong targets for therapies in the treatment of advanced melanoma.
NCCN ORP vice resident Diane Paul said the two research projects would help in understanding of both drugs and translating that knowledge into improved treatments for patients with cancer.